Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …

Allogeneic hematopoietic stem-cell transplantation is a potentially curative therapy for
various hematologic diseases. An essential component of this procedure is the pre …

Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic
malignancies. However, treatment failure after initial response approaches 50%. In …

To address limitations of the currently used reduced-intensity/myeloablative conditioning
(RIC/MAC) classification scheme we aimed to develop a tool that can capture more …

The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to
CD19 chimeric antigen receptor (CAR) T-cell therapy significantly improved outcomes in …

Fludarabine is one of the most common agents given for lymphodepletion before CD19
chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data …

We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated
with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen …

Abstract N-acetyltransferase 10 (NAT10), is an acetyltransferase that regulates RNA stability
and translation processes. Association of NAT10 with several diseases including cancer …

Introduction Adoptive immunotherapy of cancer has evolved from the use of ex vivo
expanded lymphokine-activated killer cells and tumor-infiltrating lymphocytes to an …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic
landscape of haematological malignancies. However, resistance and relapse remain …